Shanghai Junshi Biosciences Dirección

Dirección controles de criterios 3/4

El CEO de Shanghai Junshi Biosciences' es Cong Li, nombrado en Nov 2021, tiene una permanencia de 2.42 años. posee directamente un 0.013% de las acciones de la empresa, con un valor de HK$3.02M. La antigüedad media del equipo directivo y de la junta directiva es de 3.1 años y 5.8 años, respectivamente.

Información clave

Cong Li

Chief Executive Officer (CEO)

CN¥4.2m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.5yrs
Participación del CEO	0.01%
Permanencia media de la dirección	2.7yrs
Promedio de permanencia en la Junta Directiva	5.9yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Cong Li (59 yo)

2.5yrs

Permanencia

CN¥4,202,800

Compensación

Mr. Cong Li has been Co-Chief Executive Officer and Executive Director at Shanghai Junshi Biosciences Co., Ltd. since November 2, 2021 and served as Non-Executive Director since December 22, 2016 until Nov...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jun Xiong	Executive Chairman	9.2yrs	CN¥5.22m	8.92% CN¥ 2.5b
Cong Li	Co-CEO & Executive Director	2.5yrs	CN¥4.20m	0.013% CN¥ 3.6m
Jianjun Zou	GM, CEO & Executive Director	less than a year	CN¥4.32m	sin datos
Ning Li	Executive Vice-Chairman of the Board	5.9yrs	CN¥9.16m	0.0051% CN¥ 1.4m
Baohong Xu	Financial Director	3.5yrs	CN¥1.15m	0.00071% CN¥ 196.1k
Zhuobing Zhang	Deputy GM & Executive Director	no data	CN¥4.76m	0.0041% CN¥ 1.1m
Sheng Yao	Senior VP & Executive Director	no data	CN¥5.01m	sin datos
Gang Wang	Deputy GM	4.8yrs	CN¥8.97m	0.0010% CN¥ 281.7k
Lu Yuan	Assistant to GM & Chief of Internal Audit Department	3.5yrs	sin datos	sin datos
Qian Wei	Chief Commercial Officer	2.8yrs	sin datos	sin datos
Patricia Keegan	Chief Medical Officer	no data	sin datos	sin datos
Xin Li	Executive Director	less than a year	sin datos	0.0096% CN¥ 2.7m

2.7yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1877 se considera experimentado (3.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jun Xiong	Executive Chairman	9.2yrs	CN¥5.22m	8.92% CN¥ 2.5b
Cong Li	Co-CEO & Executive Director	7.4yrs	CN¥4.20m	0.013% CN¥ 3.6m
Jianjun Zou	GM, CEO & Executive Director	1.9yrs	CN¥4.32m	sin datos
Ning Li	Executive Vice-Chairman of the Board	5.9yrs	CN¥9.16m	0.0051% CN¥ 1.4m
Zhuobing Zhang	Deputy GM & Executive Director	7.4yrs	CN¥4.76m	0.0041% CN¥ 1.1m
Sheng Yao	Senior VP & Executive Director	7.4yrs	CN¥5.01m	sin datos
Gang Wang	Deputy GM	less than a year	CN¥8.97m	0.0010% CN¥ 281.7k
Xin Li	Executive Director	less than a year	sin datos	0.0096% CN¥ 2.7m
Yu Wu	Chairman of the Board of Supervisors	5.9yrs	sin datos	sin datos
Yi Tang	Non-Executive Director	9yrs	sin datos	0.79% CN¥ 218.0m
Chun Zhang	Independent Non-Executive Director	3.9yrs	CN¥200.00k	sin datos
Xiaoyuan Feng	Independent Non-Executive Director	2.4yrs	CN¥208.60k	sin datos

5.9yrs

Permanencia media

55.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 1877 se considera experimentada (5.8 años de antigüedad promedio).

Shanghai Junshi Biosciences Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023

Recent updates

First quarter 2024 earnings released

Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region

No longer forecast to breakeven

Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥2.32 loss per share (vs CN¥2.60 loss in FY 2022)

Full year 2023 earnings released: CN¥2.28 loss per share (vs CN¥2.60 loss in FY 2022)

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List

Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

New minor risk - Profitability

Third quarter 2023 earnings released: CN¥0.42 loss per share (vs CN¥0.75 loss in 3Q 2022)

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

Second quarter 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.56 loss in 2Q 2022)

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint

First quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥0.44 loss in 1Q 2022)

Now 21% undervalued after recent price drop

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China

Now 26% undervalued

Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvita Life Sciences Co., Ltd. Announce Progress of the Clinical Studies of VV116

Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 Study of Vv116 Versus Paxlovid for Adults At High Risk for Progression to Severe Covid-19

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization Application of Toripalimab

Shanghai Junshi Biosciences Co., Ltd Submits Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency

Shanghai Junshi Biosciences Co., Ltd. Announces Receiving the Notice of Approval for Supplemental Drug Application Issued by the National Medical Products Administration

No longer forecast to breakeven

Shanghai Junshi Biosciences Co., Ltd. Announces Submission of A Marketing Authorization Application to the European Medicines Agency for Toripalimab

Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Clinical Trial Issued by the National Medical Products Administration

Third quarter 2022 earnings released: CN¥0.75 loss per share (vs CN¥0.50 loss in 3Q 2021)

Shanghai Junshi Biosciences Co., Ltd. to Report Nine Months, 2022 Results on Oct 28, 2022

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology

Shanghai Junshi Biosciences Co., Ltd Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: CN¥0.57 loss per share (vs CN¥0.37 loss in 2Q 2021)

Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

Shanghai Junshi Biosciences Co., Ltd. to Report Q2, 2022 Results on Aug 30, 2022

Shanghai Junshi Biosciences Co., Ltd. Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma

Now 21% undervalued after recent price drop

Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Issued by National Medical Products Administration

Forecast to breakeven in 2024

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. and Risen (Suzhou) Pharma Tech Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS105

Shanghai Junshi Biosciences Co., Ltd. Appoints Zou Jianjun as Executive Director

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 29, 2022

Shanghai Junshi Biosciences Co., Ltd. Announces PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate Covid-19

Shanghai Junshi Biosciences Co., Ltd. Announces Vv116 Versus Paxlovid for Early Treatment of Mild to Moderate Covid-19 Reaches Primary Endpoint in Phase Iii Registrational Clinical Study

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Paclitaxel and Cisplatin in First-Line Treatment of Advanced or Distant Metastatic Esophageal Squamous Cell Carcinoma